引用本文:[点击复制]
[点击复制]
【打印本页】 【在线阅读全文】【下载PDF全文】 查看/发表评论下载PDF阅读器关闭

←前一篇|后一篇→

过刊浏览    高级检索

本文已被:浏览 160次   下载 95 本文二维码信息
码上扫一扫!
加味血府逐瘀胶囊治疗心脏X综合征心血瘀阻证41例
曹 瑛,吴鹏飞,曹 玲
0
(湖南中医药大学附属衡阳医院,湖南 衡阳,421001)
摘要:
目的:探讨加味血府逐瘀胶囊治疗心脏X综合征(CSX)心血瘀阻证的临床疗效及作用机制。方法:将82例CSX心血瘀阻证患者随机分为治疗组和对照组,每组各41 例。对照组给予常规西药治疗,治疗组在对照组的基础上给予加味血府逐瘀胶囊治疗,疗程均为30 d。比较2组治疗前后加拿大心血管病学会(CCS)分级、西雅图心绞痛量表(SAQ)积分、中医证候积分、内皮因子(血清内皮素-1、一氧化氮)水平、炎症因子(C反应蛋白、白细胞介素-6)水平、心电图平板运动试验结果,并评估临床疗效及中医证候疗效。结果:总有效率治疗组为95.12%(39/41),高于对照组的70.73%(29/41),差异有统计学意义(P<0.05)。中医证候疗效总有效率治疗组为92.68%(38/41),高于对照组的65.85%(27/41),差异有统计学意义(P<0.01)。2组CCS分级、SAQ积分、中医证候积分、内皮因子及炎症因子各项指标水平治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.01或P<0.05);治疗组心电图平板运动试验阳性率降低(P<0.05)。结论:加味血府逐瘀胶囊能改善CSX心血瘀阻证患者中医证候和心绞痛严重程度,减轻炎症反应,降低心电图平板运动试验阳性率,改善血管内皮功能,保护心功能和冠脉循环,值得临床推广。
关键词:  心脏X综合征  心血瘀阻证  血府逐瘀胶囊
DOI:
Clinical effect of Jiawei Xuefu Zhuyu capsules in treatment of cardiac syndrome X with stagnant blockade of heart blood: An analysis of 41 cases
CAO Ying,WU Pengfei,CAO Ling
(Hengyang Hospital Affiliated to Hunan University of Chinese Medicine,Hengyang 421001,Hunan,China)
Abstract:
Objective: To investigate the clinical effect and mechanism of action of Jiawei Xuefu Zhuyu capsules in the treatment of cardiac syndrome X (CSX) with stagnant blockade of heart blood.Methods: A total of 82 CSX patients with stagnant blockade of heart blood were randomly divided into treatment group and control group,with 41 patients in each group.The patients in the control group were given conventional Western medicine treatment,while those in the treatment group were given Jiawei Xuefu Zhuyu capsules in addition to the treatment in the control group,and the course of treatment was 30 days for both groups.The two groups were compared in terms of Canadian Cardiovascular Society (CCS) grading,Seattle Angina Questionnaire (SAQ) score,traditional Chinese medicine (TCM) syndrome score,the levels of endothelial factors (endothelin-1 and nitric oxide) and inflammatory factors (C-reactive protein and interleukin-6),and electrocardiographic treadmill exercise test results before and after treatment,and clinical outcome and the treatment outcome of TCM syndrome were also assessed.Results: The treatment group had a significantly higher overall response rate than the control group [95.12% (39/41) vs 70.73% (29/41),P<0.05],and the treatment group also had a significantly higher overall response rate of TCM syndrome than the control group [92.68% (38/41) vs 65.85% (27/41),P<0.01].After treatment,both groups had significant reductions in CCS grade,SAQ score,TCM syndrome score,and the levels of endothelial factors and inflammatory factors,and the treatment group had significantly lower levels of these indicators than the control group (P<0.01 or P<0.05).The electrocardiographic treadmill exercise test showed a significant reduction in positive rate in the treatment group(P<0.05).Conclusion: For CSX patients with stagnant blockade of heart blood,Jiawei Xuefu Zhuyu capsules can improve TCM syndrome and the severity of angina pectoris,alleviate inflammatory response,reduce the positive rate of electrocardiographic treadmill exercise test,improve vascular endothelial function,and protect cardiac function and coronary circulation,and therefore,it holds promise for clinical application.
Key words:  cardiac syndrome X  stagnant blockade of heart blood  Xuefu Zhuyu capsules

用微信扫一扫

用微信扫一扫